FLT3 and acute myeloid leukemia: The intermediate risk group includes all AML cases with FLT3-ITD; mutated NPM1 with FLT3-ITD; wild-type NPM1 with FLT3-ITD; with translocations: t(9;11)(p21.3;q23.3) involving the MLLT3::KMT2A genes, and all the cytogenetic and/or molecular abnormalities not classified as favorable or adverse [24].